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Abstract Hypertrophic cardiomyopathy (HCM) is an
autosomal dominant disorder resulting from mutations in
genes for at least 15 various sarcomere-related proteins
including cardiac b-myosin heavy chain, cardiac myosin-
binding protein C, and cardiac troponin T. The troponin
T gene (TNNT2) mutation has the third incidence of
familial HCM, and the genotype–phenotype correlation
of this gene still remains insufficient in Japanese familial
HCM. Therefore, in the present study, we focused on
screening the TNNT2 mutation in 173 unrelated Japanese
patients with familial HCM, and found three reported
mutations and a new mutation of TNNT2 in 11 individ-
uals from four families. In these families, two individuals
from one family had double mutations, Arg130Cys and
Phe110Ile, six individuals from two other families had an
Arg92Trp mutation, and one individual of another family
had a new mutation, Ile79Thr, of TNNT2. The phenotype
of each family was often different from reported cases,
even if they had the same genetic mutation. In addition,
families with the same genetic mutation showed a similar
trend in the phenotype, but it was not exactly the same.
However, sudden death in youth was observed in all of
these families. Although the type of genetic mutation is
not useful for predicting prognosis in HCM, the possi-
bility of sudden cardiac death remains. Therefore, the
prognosis of individuals bearing the TNNT2 mutation
with familial HCM should be more carefully observed
from birth.
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Introduction
Hypertrophic cardiomyopathy (HCM) is characterized by
left and/or right ventricular hypertrophy, with predominant
involvement of the interventricular septum in the absence
of other causes of hypertrophy, such as hypertension, val-
vular heart disease, or metabolic disease [1–7].
Familial HCM is an autosomal dominant disorder
caused by mutations in genes that encode sarcomere pro-
teins. It has been reported that at least 15 genes are
implicated in 55–70 % of HCM, and the major genes
causing HCM include cardiac b-myosin heavy chain
(MYH7), a-tropomyosin, cardiac troponin T (TNNT2),
cardiac myosin-binding protein C (MYBPC3), cardiac tro-
ponin I (TNNI3), cardiac myosin regulatory light chains
(MYL2), and cardiac myosin essential light chains (MYL3)
[1, 4, 5, 8–11].
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Cardiac troponin T is a thin-filament protein that takes
part in muscle contraction. The troponin complex on the
actin filament regulates the force and velocity of muscle
contraction. Troponin C functions as a calcium receptor
while troponin I inhibits adenosine triphosphatase (ATP-
ase) activity when bound to actin. Troponin T fixes the
troponin group to tropomyosin. During relaxation, the
troponin group is bound to actin and tropomyosin, blocking
the interaction of myosin and actin [12].
TNNT2 was mapped to chromosome 1q32. Mutations of
TNNT2 were thought to account for approximately 15 % of
familial HCM, with most missense mutations located in
exons 8–16 [3], and were associated with a particularly
severe form of the disease characterized by a poor overall
prognosis with a high incidence of sudden death despite
only mild left ventricular hypertrophy (LVH) [1–4]. Most
TNNT2 mutations of familial HCM alter the contractile
properties of cardiac muscle, especially the Ca2? sensi-
tivity of force development and ATPase activity in vitro
and in vivo [13–17].
Previous reports have suggested that there is a more
consistent relationship between certain genetic mutations
and clinical outcome, allowing for the classification of
‘‘benign’’ and ‘‘malignant’’ mutations [18–30]. For exam-
ple, a favorable prognosis has been reported in patients
with a Phe110Ile mutation of the TNNT2 mutation (in 16
individuals of 6 Japanese families) [19, 20]. From these
data, genetic analysis and determination of genotype were
thought to be important for assisting with patient
management.
However, these findings were based on limited experi-
ence; to date, only 30 different mutations have been
identified in TNNT2 [9–11, 18]. In addition to this genetic
diversity, the phenotypic expression of these mutations
varies considerably, ranging from asymptomatic individu-
als with a normal life expectancy to those with sudden
cardiac death or the need for an early heart transplant.
Clinical parameters such as the degree of LVH, the pres-
ence or absence of a left ventricular outflow tract gradient,
and electrophysiology testing have not been predictive
markers of poor prognosis [1–5]. More recently, it was
reported that late gadolinium enhancement with cardiac
magnetic resonance can be a predictive marker of the
ventricular arrhythmia and poor prognosis in HCM [31].
In recent years, mutation-specific risk stratification was
considered to be not possible, but genetic test-based risk
stratification seemed to be clinically informative [32].
The TNNT2 mutation has the third-ranked incidence of
familial HCM, and the genotype–phenotype correlation of
this gene still remains insufficient in Japanese familial
HCM. Therefore, in the present study we focused on
screening the TNNT2 mutation.
Patients and methods
Subjects
We genetically evaluated 173 patients (101 men and 72
women; 0–79 years old, median age 20 years) who were
clinically diagnosed with familial HCM.
Pediatric patients with HCM were recruited from Tokyo
Women’s Medical University. Written informed consent
was obtained from all study subjects in accordance with the
Declaration of Helsinki. If patients were younger than 16
years, informed consent was given by their guardians. We
assessed each patient by taking their history and perform-
ing a physical examination, and reviewed their medical
records. All assessments were done with the approval of
the Ethics Committees of Tokyo Women’s Medical
University.
The diagnosis of HCM was determined through clinical
evaluation, chest radiography, electrocardiography, echo-
cardiography, and cardiac catheterization based on current
international consensus criteria.
Diseases of the heart, hypertension, valvular heart dis-
ease, or metabolic disease attributable to HCM were
excluded from this study by pediatric cardiologists.
Mutation screenings
Genomic DNA was prepared from peripheral blood lym-
phocytes or lymphoblast cell lines transformed by the
Epstein–Barr virus, as described previously [33]. TNNT2
coding regions and exon–intron boundaries, including
regions approximately 30–100 bp upstream and down-
stream from the exons, were amplified from genomic DNA
using primers, as described in previous reports [34, 35].
Genomic DNA (50 ng) was amplified through the use of
primers designed from flanking intron sequences (Table 1).
Amplified products were purified using a MultiScreen
polymerase chain reaction (PCR) plate (Millipore, Bille-
rica, MA, USA) and directly sequenced using the ABI-
PRISM BigDye-terminator cycle sequencing reaction kit
and ABI 3130xl genetic analyzer (Applied Biosystems,
Foster City, CA, USA). When a mutation was detected, we
confirmed that it was not presenting 363 Japanese normal
chromosomes by direct sequencing.
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The PCR conditions of these genes were modified and
fragments were analyzed by electrophoresis, as described
previously [36, 37].
Proband patients bearing TNNT2 mutations were addi-
tionally examined for reported HCM mutations, the coding
regions of MYH7, MYBPC3, TNNI3, a-tropomyosin,
MLY2, MLY3, and all exons, and a promoter region of the
a-galactosidase A gene. Primer sequences and detailed
PCR conditions for these additional analyses are available
upon request. Reference sequences and single-nucleotide
polymorphism information were obtained from the
National Center for Biotechnology Information.
Results
Clinical report and DNA analysis
To investigate mutations of TNNT2, we performed DNA
analysis in 173 unrelated Japanese patients with familial
HCM. We identified three reported mutations and a new
mutation of TNNT2 in 11 individuals from four families
(A, B, C, D) (Table 2).
In family A, all five members who carried or were
suspected of having HCM also had arrhythmia. Four of
them had blocks, including a complete atrioventricular
block (CAVB) and complete right bundle branch block
(CRBBB) (Fig. 1; II-1, 6, III-1, 2), and one had brady-
cardia. Two of them died suddenly (Fig. 1; I-2, III-1), and
one was a ventricular fibrillation (Vf) survivor (Fig. 1; III-2).
The proband (Fig. 1; III-2), aged 12 years, with sinus
rhythm (SR) and a CRBBB, had an episode of Vf, and her
elder brother (Fig. 1; III-1), aged 14, also with SR and a
CRBBB, had died suddenly. Her father and her uncle had
pacemakers implanted to treat complete AV blocks. Her
mother and mother’s family had no symptoms or abnormal
findings. The proband and her brother and father (Fig. 1;
III-2, III-1, I-2) showed mild LVH (maximum wall thick-
ness \20 mm). All three members underwent cardiac
catheterization, and showed significant left ventricular
relaxation abnormalities.
DNA analysis showed that the proband and her elder
brother had the double reported mutations, Arg130Cys and
Phe110Ile, of TNNT2 (Fig. 1). Her father, who had
arrhythmia and mild HCM, had the Phe110Ile mutation,
and her mother (II-60), who had no symptoms or abnormal
findings, had the Arg130Cys mutation.
In family B, 3 of 10 members who carried or were
suspected of having HCM were thought to have obstructive
hypertrophic cardiomyopathy. Two female members (Fig. 2;
II-4, III-9) died suddenly at a young age. The proband (Fig.
2; III-7) showed apical hypertrophy and apical aneurysm at
a comparatively young age. Her aunt (Fig. 2; II-4), who
had a heart murmur, was thought to have hypertrophic
obstructive cardiomyopathy (HOCM), and died when she
was 19 years old. Her younger sister (Fig. 2; III-9) did not
show obstructive HCM, but died suddenly when she was
21 years old. Her grandmother (Fig. 2; I-1) died suddenly
at the age of 50 years. DNA analysis showed that the
proband (Fig. 2; III-7), her son (Fig. 2; IV-3), and her
cousin (Fig. 2; III-2), who carried HCM, had an Arg92Trp
mutation of TNNT2.
In family C, the proband (Fig. 3; IV-3), her mother (Fig. 3;
III-3), and her grandmother (Fig. 3; II-3) showed mild car-
diac hypertrophy (maximum wall thickness \20 mm) and
asymmetric septal hypertrophy, and her myocardial hyper-
trophy had been gradually increasing. Her mother was sus-
pected of having a shifting dilated phase by recent cardiac
magnetic resonance imaging (MRI). The proband (Fig. 3;
IV-3) had symptomatic West syndrome following perinatal
Table 1 Primers used for
amplification of fragments from
TNNT2
Exon Forward (50–30) Reverse (50–30)
2 GAGCTCTTCTGAGGAAGGCA CTACCCAGAATCCGAGGGAC
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brain damage, and was treated with corticotropin. DNA
analysis showed that the proband (Fig. 3; IV-3) and her
mother (Fig. 3; III-3) had the Arg92Trp mutation of TNNT2.
In family D, two of three members who carried or were
suspected of having HCM died suddenly (Fig. 4; I-4, III-3),
and one was a Vf survivor (Fig. 4; III-2). The proband
(Fig. 4; III-2) had relatively strong cardiac hypertrophy
(maximum wall thickness [20 mm), and cardiac standstill
from ventricular fibrillation at the age of 24 years. Her
cousin (Fig. 4; III-3) died suddenly at a young age (13
years), and her granduncle also died at the age of 40. DNA
analysis shows that the proband had the 236T ? C
nucleotide alteration. This transition was observed in codon
79, and converted an isoleucine residue to a threonine
residue (Fig. 5a). Ile79Thr occurred in conserved residues
found in TNNT2 orthologues of human, mouse, rat, cat, and
Fig. 1 Pedigree and phenotype
of Family A. Pedigree with
three generations (Roman
Numerals), the propositus is
denoted by an arrow. Further
clinical data for family members





right bundle-branch block, Vf
ventricular fibrillation
Fig. 2 Pedigree and phenotype
of Family B. Pedigree with four
generations (Roman Numerals),
the propositus is denoted by an
arrow. Further clinical data for
family members is detailed in
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ox (Fig. 5b). This mutation was not observed in 363
chromosomes from unaffected Japanese populations. The
proband (Fig. 4; III-2) also had a 5-bp (CTTCT) deletion/
deletion polymorphism of intron 3 of TNNT2 (Fig. 6a).
To clarify the clinical importance of this polymorphism,
we performed genetic analysis in 47 HCM patients from
173 unrelated Japanese patients with familial HCM. In
these 47 patients, 24 had the deletion/deletion polymor-
phism (51 %, 14 men and 10 women; 0–72 years old,
median age 30 years old). Five of the 24 (21 %) patients
who had the deletion/deletion polymorphism were diag-
nosed with apical HCM or HOCM. In 6 of the 10 (60 %)
with available data of echocardiography among these 24
patients, the maximum wall thickness was more than 30
mm. On the other hand, in the 47 HCM patients, the
remaining 23 did not have the deletion/deletion polymor-
phism, but had the deletion/insertion or insertion/insertion
polymorphism (49 %, 15 men and 8 women; 0–76 years
old, median age 18 years). Two of the 23 (9 %) patients
were diagnosed with apical HCM, and there were no
Fig. 3 Pedigree and phenotype
of Family C. Pedigree with four
generations (Roman Numerals),
the propositus is denoted by an
arrow. Further clinical data for
family members is detailed in




Fig. 4 Pedigree and phenotype
of Family D. Pedigree with four
generations (Roman Numerals),
the propositus is denoted by an
arrow. Further clinical data for
family members is detailed in
the table. HCM hypertrophic
cardiomyopathy, Vf ventricular
fibrillation
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HOCM patients. Two of the seven (29 %) with available
data of echocardiography among these 23 patients showed
the maximum wall thickness of more than 30 mm.
Discussion
Previous studies have reported familial HCM cases where a
consistent relationship between certain genetic mutations
and clinical outcome was observed, allowing for the clas-
sification of ‘‘benign’’ and ‘‘malignant’’ mutations [18–30].
However, in recent years it was considered that the
specific gene mutation cannot be the sole factor that dictates
clinical phenotype. Since around 1 %–2 % of all patients
with HCM had a ‘‘benign’’ or ‘‘malignant’’ mutation,
mutation type was not seen to be clinically useful in pre-
dicting prognosis in HCM given this very low incidence rate
[32, 38–40]. In addition, it was reported that mutation of a
sarcomeric protein gene can cause RCM, HCM, and DCM
within the same family, and patients with a benign mutation
experienced a very serious clinical course [41, 42].
In the present study, the phenotype of each family was
often different from reported cases, even if they had the
same genetic mutation. In addition, families with the same
genetic mutation showed a similar trend in the phenotype,
but it was not exactly the same. However, sudden death in
youth was observed in all of these families. On the other
hand, there seemed to be a family with a ‘‘malignant’’
mutation, which did not show the phenotype of HCM or a
family history of sudden death.
For example, in family A, two TNNT2 mutations were
found, the Arg130 Cys and Phe110Ile mutations. The
Arg130 Cys mutation has been reported by a Chinese
research group [21], whose clinical features had an early
onset, syncope, sudden death in youth, heart failure, and
arrhythmia as atrial fibrillation. The Phe110Ile mutation
has been reported to show a favorable prognosis, and have
comparatively slight hypertrophy or apical hypertrophy
Fig. 5 a The new Ile79Thr mutation of TNNT2 (Exon 8). b The position of the 79th Ile codes for the binding site of tropomyosin. This domain is
well preserved in mammals
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(in 16 individuals of 6 Japanese Families) [19, 20]. Both of
these reported pedigrees are Asian.
In family A, whereas the proband and her elder brother,
who carried these two mutations, showed similar reported
phenotypes of the Arg130 Cys mutation [21], her mother
and mother’s family members, who had the Arg130Cys
mutation, showed no abnormal clinical features such as
cardiac hypertrophy, sudden death, or abnormal electro-
cardiograms. Furthermore, her father and father’s family
members, who had the Phe110Ile mutation, showed atrio-
ventricular blocks, and these phenotypes have not been
reported.
In family B, an Arg92Trp mutation of TNNT2 was
found. The mutation showed comparatively slight cardiac
hypertrophy or a high incidence of sudden death in males
(19 individuals of two mixed racial families) [22–24].
However, the proband and her family, who carried HCM,
showed relatively severe cardiac hypertrophy, with a high
incidence of sudden death in females.
In family C, an Arg92Trp mutation was also found. The
proband and her family, who carried HCM, showed mild
cardiac hypertrophy and asymmetric septal hypertrophy.
The proband’s myocardial hypertrophy had been gradually
increasing, and her mother had a suspected shift to the
dilated phase.
In family D, the proband carried the new mutation
Ile79Thr of TNNT2. She survived following an episode of
Vf, and her cousin died suddenly at the age of 13 years.
Previously, a mutation of the 79 residue, the Ile79Asn
mutation, had been reported [24, 25], and this mutation
also showed a poor prognosis. In our mutated case, even if
the amino acid mutation (Ile79Thr) was different from the
reported case (Ile79Asn), the patient showed a malignant
prognosis. In family D, a 5-base-pair (CTTCT) deletion/
deletion (D/D) polymorphism in intron 3 of the TNNT2 was
also found. It has been reported that this polymorphism had
caused skipping of exon 4 of TNNT2, and that the deletion
allele could be associated with a predisposition for prom-
inent LVH [42]. Although it was in a very limited range,
from our genetic study on this polymorphism we gained the
impression that a patient carrying the TNNT2 deletion/
deletion polymorphism had a stronger tendency toward
hypertrophy. To conduct further analysis, further exami-
nation including new cases is required.
We considered that, at least in Japanese familial HCM,
only the type of genetic mutation of TNNT2 did not seem
useful in distinguishing the prognosis. However, if muta-
tions were found, there was a risk of sudden death in youth.
Therefore, regardless of the type of genetic mutation, it
would be more important to observe the patient in detail
from birth in each lineage.
The development of a ‘‘case-based’’ method would be
useful to treat and help each individual, and more attention
needs to be paid toward searching for the modifier and
environmental factors including diet, lifestyle, exercise,
and the modification gene and polymorphism.
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